Market research
RGLS Regulus Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 565M
- P/E ratio
- Not available
- Analyst target
- 7
- Dividend yield
- Not available
- Beta
- 0.37
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US75915K3095
- Market cap
- 565M
- P/E ratio
- Not available
- Analyst target
- 7
- Dividend yield
- Not available
- Beta
- 0.37
About
About Regulus Therapeutics Inc
Regulus Therapeutics Inc. engages in the development of drugs designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was formerly known as Regulus Therapeutics LLC and changed its name to Regulus Therapeutics Inc. in January 2009. The company was incorporated in 2007 and is based in San Diego, California. As of June 25, 2025, Regulus Therapeutics Inc. operates as a subsidiary of Novartis AG.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the RGLS discussion.
5 years, 4 months ago
Regulus Therapeutics Inc is currently in a long term downtrend where the price is trading 30.3% below its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.3.
Regulus Therapeutics Inc's total revenue rose by 27677.8% to $5M since the same quarter in the previous year.
Its net income has increased by 73.0% to $-1M since the same quarter in the previous year.
Finally, its free cash flow grew by 163.3% to $3M since the same quarter in the previous year.
Based on the above factors, Regulus Therapeutics Inc gets an overall score of 4/5.